The Potential Role of Compounds Derived From Ultra-processed Foods in Pathogenesis of Eosinophilic Esophagitis
NCT06093204 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-07-17
Summary
Eosinophilic esophagitis (EoE) is a chronic antigen-mediated inflammatory disease of the esophagus that affects both children and adults. The incidence and prevalence of EoE is rapidly increasing in Western countries with an estimated incidence of 6.6 per 100,000 person-years (95% CI, 3-11.7) in children and 7.7 per 100,000 person-years (95% CI, 1.8-17.8) in adults. Clinically, it is characterized by various symptoms related to esophageal dysfunction, including vomiting, regurgitation, feeding difficulties, epigastric heartburn, dysphagia, or food bolus impaction, and may cause growth retardation. Diagnosis is made on the basis of clinical symptoms and histological evidence of eosinophilic infiltration of the esophagus (at least 15 eosinophils/high power microscope field (eos /hpf), excluding other etiologies of esophageal eosinophilia (gastroesophageal reflux disease, infectious esophagitis, achalasia, celiac disease and Crohn's disease, connective tissue disorders, gra ft versus host disease, drug hypersensitivity and hypereosinophilic syndromes). EoE is primarily characterized by a T helper 2 type inflammation, but the pathogenesis and the immunopathological mechanisms underlying the pathology are not yet fully understood. Recent evidence suggests that in genetically predisposed individuals, interaction with environmental factors (e.g., dietary lifestyle) may play a role in activating several inflammatory pathways and cause EoE.
Ultra-processed foods (UPFs) are food and beverage products resulting from industrial formulations, ready for consumption, typically obtained with five or more ingredients from different manufacturing processes (cooking methods, addition of additives such as stabilizers or preservatives). During the last decade, the consumption of the latter has increased significantly among the pediatric population to represent 30% of the daily caloric intake of an average child in Europe and America. Recent evidences show that UPFs favor the onset of chronic non-communicable diseases through the activation of different inflammatory pathways.
The components mostly represented in UPFs are the advanced glycation end products (AGEs), a heterogeneous group of highly oxidizing compounds that are formed through non-enzymatic reactions (Maillard reaction) between reduced sugars and free amino groups of proteins, lipids, or nucleic acids.
Evidence demonstrates that dietary AGEs are absorbed and contribute significantly to the total concentration of AGEs in the body. AGEs induce oxidative stress and inflammation, leading to structural and functional protein alterations, cellular apoptosis and multi-tissue/organ damage. These mechanisms are mediated at least in part by interactions with their cell-surface receptor for advanced glycation end-products (RAGE).
The AGEs-RAGE interaction modulates the immune response. AGEs are able to activate le mast cells, to stimulate the release of histamine and to induce a chronic inflammatory state that promotes a T helper 2 type response.
Conditions
- Esophagitis, Eosinophilic
Interventions
- OTHER
-
Dietary evaluation
Comparative evaluation of the dietary consumption of ultraprocessed foods and ultraprocessed foods-derived compounds
Sponsors & Collaborators
-
Federico II University
lead OTHER
Eligibility
- Min Age
- 3 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-12
- Primary Completion
- 2025-06-12
- Completion
- 2026-06-12
Countries
- Italy
Study Locations
More Related Trials
-
Risk Factors and Biomarkers for Diagnosis and Treatment of EoE
NCT01988285 ·Status: ACTIVE_NOT_RECRUITING
-
The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis
NCT02353078 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Eosinophilic Esophagitis: Influence of Dilation on Dysphagia and Inflammation
NCT00667524 ·Status: COMPLETED
-
Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis
NCT01479231 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
EDN and Eosinophilic Esophagitis
NCT06387030 ·Status: RECRUITING ·Phase: NA
-
Inflammatory Mediators as Potential Non-Invasive Biomarkers in Subjects With Eosinophilic Esophagitis
NCT03822325 ·Status: ACTIVE_NOT_RECRUITING
-
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
NCT00728481 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Eating With Eosinophilic Esophagitis (EoE)
NCT03581838 ·Status: COMPLETED
-
Allergy Immunotherapy in the Management of Eosinophilic Esophagitis
NCT01685034 ·Status: WITHDRAWN ·Phase: NA
-
Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis
NCT06972147 ·Status: RECRUITING
-
Food Antigen in Eosinophilic Esophagitis
NCT02434705 ·Status: COMPLETED
-
Outcome of Children With Eosinophilic Esophagitis
NCT06190080 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
NCT06665971 ·Status: RECRUITING ·Phase: PHASE4
-
Metabolomic Profiling of Eosinophilic Esophagitis
NCT03803527 ·Status: WITHDRAWN ·Phase: NA
-
Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population
NCT05176249 ·Status: ACTIVE_NOT_RECRUITING
-
Bethanechol for Eosinophilic Esophagitis
NCT02058537 ·Status: TERMINATED ·Phase: PHASE2
-
Prostaglandin and Cannabinoid Receptors in EoE
NCT04626609 ·Status: COMPLETED
-
Prospective Multicenter Nationwide Registry of Children With Eosinophilic Esophagitis
NCT03858426 ·Status: UNKNOWN
-
Routine Screening for Eosinophilic Esophagitis in Patients Presenting With Dysphagia
NCT01028235 ·Status: UNKNOWN
-
Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?
NCT01865825 ·Status: COMPLETED
-
Sensory Processing Issues in Eosinophilic Esophagitis
NCT06187753 ·Status: RECRUITING
-
Swallowing Characteristics of Pediatric Patients With Eosinophilic Esophagitis
NCT04704752 ·Status: COMPLETED
-
Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitis on Chronic Swallowed Topical Steroids
NCT05246085 ·Status: UNKNOWN
-
A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis
NCT04849390 ·Status: COMPLETED ·Phase: PHASE2
-
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
NCT06352073 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4